Patent Timeline
Below is a linear timeline of the patents , including filing dates (applied for), allowance dates (where available), publication dates (where applicable), and issue dates (granted/issued, where confirmed). Consolidated CIP-1 with the original patent (same application number) and CIP-4 with CIP-3 (same application number, with veterinary expansion noted). Events are sorted chronologically. An experimental exemption which covers all prior art was also allowed.
Date
Event Description
January 15, 2016
June 13, 2018
June 13, 2018
March 30, 2020
November 16, 2022
January 24, 2023
March 21, 2023
July 13, 2023
December 18, 2023
February 14, 2024
March 15, 2024
Filed Original Patent / CIP-1 (App. No. 14/997,046): Analgesic Formulations and Methods for Reduced Postoperative Nausea and Vomiting and Enhanced Postoperative Pain Relief; covers bupivacaine, ketamine, ketorolac.
Allowed Original Patent / CIP-1 (App. No. 14/997,046).
Issued Original Patent / CIP-1 as US 10,098,872 B1.
Filed CIP-2 (App. No. 16/834,863); expands to bupivacaine or ropivacaine, MgSO₄ or ketamine, meloxicam or ketorolac, and optional additives (epinephrine, steroids, etc.).
Allowed CIP-2 (App. No. 16/834,863).
Issued CIP-2 as US 11,559,521 B2.
Filed CIP-3 / CIP-4 (App. No. 18/187,236); CIP-3 covers bupivacaine, carprofen, dexmedetomidine, vocacapsaicin; CIP-4 expands into veterinary applications (bupivacaine, ketamine, carprofen, vocacapsaicin).
Published CIP-3 / CIP-4 as US 2023/0218600 A1.
Filed CIP-5 (App. No. 18/543,781): Synergistic Multimodal Opioid-Free Analgesic Formulation and Methods for Reduced Postoperative Nausea and Vomiting, Inflammation, and Enhanced Postoperative Pain Relief; covers dexmedetomidine and dextromethorphan; status pending (no allowance/issue as of Nov 2025).
Confirmation letter received for CIP-5 filing (Nguyen & Tarbet).
Allowed CIP-3 / CIP-4 (App. No. 18/187,236); pending issuance (no issue date confirmed as of Nov 2025).